Application note
Improve the CAR-T manufacturing process using cell differentiation insights
Efficacy is diminished due to the predominance of more differentiated cells in the final CAR-T product
Identification of various differentiated subpopulations results in the ability to optimize the CAR-T manufacturing process
The actionable insights provided by Immunomind assist when selecting the most effective composition of a CAR-T product, and allow modification of the manufacturing process
Those properties are directly associated with the differentiation status of the product. After being introduced to the antigen, naive T cells can differentiate into effector and memory cells. Terminal effector memory T cells have high lytic antitumor activity , but are limited by low proliferation and persistence properties. A less differentiated subpopulation of memory T cells has enormous proliferative potential. This provides excellent possibilities for long-term persistence in vivo, and may give rise to other subpopulations. These properties make less differentiated cell subpopulations the best candidate for application in CAR-T therapy.
The anti-tumor capability of CAR-T cells, as well as the frequency of remissions, depend on the degree of proliferation, persistence, and survival of those CAR-T cells.
Efficacy of a therapy is decreased by the predominance of more differentiated cells in the final CAR-T product
The level of differentiation within CAR-T cells is a pivotal property in the manufacture of an infusion product. When T cell subpopulations become more differentiated, the chance for the CAR-T drug to trigger tumor regression declines profoundly. As a result, CAR-T manufacturing requires the selection of CAR-T cells with a suitable differentiation status, accompanied by the prevalence of less-differentiated subpopulations such as:
• T naive (Tn)
• T stem cell memory (Tscm)
• T central memory (Tcm)
ImmunoMind simultaneously determines the composition and differentiation status of subpopulations in a CAR-T product, with single-cell precision.
The AI-augmented platform provided by Immunomind allows T cell subpopulations in a CAR-T product to be highlighted, based on the differentiation status. This works for: T-naive cells, T stem cell memory, T central memory, etc. The platform helps companies leverage single-cell multi-omics technologies to improve the manufacturing process for CAR-T. This assists the medical scientist when selecting the best strategy to optimize the product composition for CAR-T.
You no longer need to perform complicated analyses and long-term calculations! With ImmunoMind you can:
Detect all phenotypes of T cell subpopulations
Evaluate the key parameters of the CAR-T product (proliferation, persistence, cytotoxicity)
Perform quality control at every stage of the manufacturing process
Select the optimal environment for the proper production of the CAR-T product
Select the best T cell therapy candidates early with ImmunoMind
• UC Berkeley SkyDeck company
Who we are
How we work
• We have already helped drug developers to boost 6 T cell therapies
• Trusted by City of Hope,
MD Anderson Cancer, and others
• Partnerships
• Strategic alliances
• Collaborations
• Contract research
To download the full application note as a PDF file